BioSpace News Archive

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation (ESRD + AFib).

PX Solutions, is launching to enable hospitals and long term care centres to improve patient and caregiver experiences and improve patient outcomes.

ROMEG Therapeutics, LLC (“Romeg”), an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,564,909 (the ‘909 patent) directed to the methods and composition of ROMEG’s proprietary formulation of pilocarpine.

Jaguar Health, Inc. and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar’s Canalevia® (crofelemer delayed-release tablets) prescription drug product effective January 31, 2023.

Atreo, Inc., a Clinical Development SaaS company committed to modernizing and simplifying RTSM delivery, has announced release of v1.2 of their next generation platform in advance of SCOPE 2023.

Today, Qrypt, which offers the only solution to remove encryption keys from transmission, announces the launch of its new US-developed, sourced, and hosted QRNG as part of its Quantum Entropy cloud service.

Aeolian Biotech Corp. today announced that Tyler Martin, M.D., Chief Executive Officer of Aeolian, will present a Company overview at the BIO CEO & Investor Conference on Monday, February 6, 2023 at 10:15 am ET. The conference is being held at the New York Marriott Marquis in New York City, February 6-7, 2023.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2022 results on Wednesday, March 1, 2023.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.

Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla.